Aveanna Healthcare (NASDAQ:AVAH) Issues Quarterly Earnings Results

Aveanna Healthcare (NASDAQ:AVAH) posted its quarterly earnings results on Thursday. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.02, FiscalAI reports. The company had revenue of $695.54 million for the quarter, compared to analysts’ expectations of $679.48 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%.

Here are the key takeaways from Aveanna Healthcare’s conference call:

• Aveanna reported Q3 revenue of $695.5 million, up 11.8%, and adjusted EBITDA of $100.1 million, up 25% year over year. Management raised 2026 guidance to revenue above $2.695 billion and adjusted EBITDA above $374 million.
• Growth was broad-based, with all three segments reporting higher revenue; Home Health and Hospice grew 15.6%, supported by 19.6% more admissions and 24% more episodes. Management raised its long-term organic growth outlook for Private Duty Services to 5%–6% and Home Health and Hospice to 8%–10%, while reaffirming 8%–10% for Medical Solutions.
• California’s planned $60 million PDN rate investment is currently viewed by the state as a supplemental payment for only the first half of 2027, while Aveanna is advocating for it to become permanent. The company said it will not make meaningful base-wage increases for California nurses until it has more certainty about ongoing reimbursement.
• Year-to-date operating cash flow was $157.5 million and free cash flow was $141.2 million; liquidity totaled $492 million, and the company said substantially all variable-rate debt is hedged through December 2029. Aveanna plans to pursue acquisitions while targeting leverage below 3x in 2027.
• Management expects Q4 to be seasonally choppy around the holidays and noted that Q4 2025 had an extra week, making year-over-year comparisons tougher. It said a mid-$90 million range is a prudent Q4 adjusted EBITDA planning anchor.

Aveanna Healthcare Stock Down 4.7%

Shares of Aveanna Healthcare stock traded down $0.57 on Friday, hitting $11.66. 1,015,173 shares of the company traded hands, compared to its average volume of 2,039,156. Aveanna Healthcare has a 12-month low of $5.93 and a 12-month high of $14.71. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 4.47. The company has a market cap of $2.55 billion, a PE ratio of 9.46, a PEG ratio of 0.80 and a beta of 2.03. The company has a 50-day moving average price of $13.06 and a 200 day moving average price of $9.44.

Insider Activity

In other news, major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares of the stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $143,704,885.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Paul Vigano sold 14,500,002 shares of the business’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $166,750,023.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 48,566,081 shares of company stock valued at $558,509,932. 5.30% of the stock is currently owned by company insiders.

Trending Headlines about Aveanna Healthcare

These are some of the AVAH headlines that stood out recently:

• Positive Sentiment: Q3 adjusted earnings were $0.23 per share, above the $0.21 consensus and up from $0.15 a year earlier. Revenue of $695.5 million also beat estimates of $679.5 million. Aveanna Q3 earnings and revenue beat estimates
• Neutral Sentiment: Aveanna identified hospice as a priority for mergers and acquisitions, which could offer a growth avenue, though acquisitions may require capital. Hospice an M&A priority for Aveanna
• Negative Sentiment: Aveanna froze a planned California nurse base-wage increase amid uncertainty over state rates. While this may restrain costs, reimbursement uncertainty and caregiver staffing pressures could weigh on growth. The company’s leverage and Medicaid exposure remain concerns for investors. California nurse wage increase frozen

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Truist Financial upped their target price on Aveanna Healthcare from $11.00 to $15.00 and gave the company a “hold” rating in a report on Monday, August 24th. BMO Capital Markets lifted their price target on Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, August 14th. Royal Bank Of Canada restated an “outperform” rating on shares of Aveanna Healthcare in a report on Friday. Raymond James Financial restated a “strong-buy” rating on shares of Aveanna Healthcare in a report on Thursday. Finally, Weiss Ratings raised shares of Aveanna Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.25.

Aveanna Healthcare Company Profile

Aveanna Healthcare Holdings Inc. is a U.S. provider of home-based healthcare services for children and adults with complex medical needs. Its services include private-duty nursing and personal care, home health nursing and therapy, and hospice care, helping patients receive support in their homes and communities. The company also provides medical supplies and related services, including products used for enteral nutrition. Aveanna serves patients and families across multiple states through a network of clinicians, caregivers, and local operations.